Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-MUSE: AdMSC in Systemic Scleroderma
NCT07326033Phase 2Not yet recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jan 2026
- Primary completion
- Apr 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial in systemic sclerosis (SSc) comparing AdMSC with Placebo (2 arms). Primary endpoint: Change in the Mouth Handicap in Systemic Sclerosis scale at 12 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
adipose derived mesenchymal stromal cells
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07326033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07326033.